Business Context and Reporting Period
The provided filing is a Form 10-Q for Zeta Acquisition Corp. II, not Whitehawk Therapeutics, Inc. It covers the quarter and six months ended June 30, 2013, and was filed August 14, 2013. Zeta was a development-stage blank-check and shell company formed to identify and complete a business combination. It had no operating business, no revenues, and no identified target.
The company reported 5,000,000 common shares outstanding as of August 14, 2013. Its financial statements were unaudited.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2013 | Six Months Ended June 30, 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating loss | $5,456 | $10,262 |
| Interest expense | $1,293 | $2,550 |
| Net loss | $6,749 | $12,812 |
| Basic and diluted loss per share | $0.00 | $0.00 |
| Net cash used in operating activities | Not presented | $11,187 |
| Net cash provided by financing activities | Not presented | $25,000 |
At June 30, 2013, cash and cash equivalents were $18,420, compared with $4,607 at December 31, 2012. Total current assets were $18,420, while current liabilities were $126,773. Liabilities included $110,000 of stockholder notes payable, $13,848 of accrued interest, $2,750 of accrued expenses, and $175 of accounts payable.
Stockholders’ deficit was $108,353 at June 30, 2013, compared with $95,541 at December 31, 2012. No meaningful revenue or operating margin analysis is applicable because the company had no revenue or active operations.
Material Changes Versus Prior Comparable Period
- Three-month net loss increased to $6,749 from $6,303 in the second quarter of 2012.
- Six-month net loss increased to $12,812 from $11,665 in the first six months of 2012.
- Cash used in operating activities improved to $11,187 from $19,814 in the prior-year six-month period.
- Financing proceeds were $25,000 in both six-month periods; the 2013 proceeds came from additional stockholder loans.
- Cash increased by $13,813 during the first six months of 2013, compared with a $5,186 increase during the prior-year period.
- Current liabilities increased to $126,773 from $103,648 at December 31, 2012, principally because stockholder notes payable increased from $85,000 to $110,000.
Guidance, Outlook, Risks, and Unusual Items
Management planned to continue searching for a suitable acquisition candidate and expected to incur costs for SEC reporting and acquisition investigations. The company had not contacted representatives of other entities regarding a business combination since its registration statement became effective.
Management stated that continued operations depend on obtaining additional financing, including related-party advances, equity financing, or funding through a reverse merger. The company cannot assure that financing will be available or that it can meet cash requirements for at least the next twelve months. The financial statements were prepared on a going-concern basis, but management identified substantial dependence on future financing and a successful business combination.
In June 2013, stockholders, including officers and directors, advanced an aggregate $25,000 under unsecured promissory notes bearing 6% annual interest and payable on demand. Upon default, the interest rate on unpaid principal increases to 12% per annum. The company had no material pending legal proceedings and no material off-balance-sheet arrangements.
The company reported that disclosure controls and procedures were effective as of June 30, 2013, with no material changes in internal control over financial reporting during the quarter.
Investor Verification Priorities
- Verify the issuer identity: the supplied filing names Zeta Acquisition Corp. II, while the request identifies Whitehawk Therapeutics, Inc.
- Confirm the terms, holders, maturity, and default provisions of the $25,000 stockholder notes issued in June 2013.
- Assess the company’s ability to continue as a going concern given $18,420 of cash, $126,773 of current liabilities, no revenue, and reliance on related-party funding.
- Determine whether any business combination was identified or completed after June 30, 2013.
- Review subsequent filings for additional financing, changes in control, dilution, or conversion of the shell company into an operating business.